Wedge Capital Management L L P NC Boosts Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Wedge Capital Management L L P NC boosted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 65,531 shares of the specialty pharmaceutical company’s stock after buying an additional 1,958 shares during the period. Wedge Capital Management L L P NC owned approximately 0.32% of ANI Pharmaceuticals worth $3,613,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in ANI Pharmaceuticals by 5.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,132,378 shares of the specialty pharmaceutical company’s stock valued at $65,746,000 after buying an additional 58,204 shares during the period. Global Alpha Capital Management Ltd. raised its holdings in ANI Pharmaceuticals by 15.9% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 525,528 shares of the specialty pharmaceutical company’s stock valued at $30,512,000 after buying an additional 72,200 shares during the period. Invesco Ltd. raised its holdings in ANI Pharmaceuticals by 185.4% in the 3rd quarter. Invesco Ltd. now owns 339,735 shares of the specialty pharmaceutical company’s stock valued at $19,725,000 after buying an additional 220,690 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in ANI Pharmaceuticals by 287.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 146,989 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after buying an additional 109,015 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in ANI Pharmaceuticals by 9.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 123,717 shares of the specialty pharmaceutical company’s stock valued at $7,183,000 after buying an additional 10,234 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ANIP has been the topic of several research analyst reports. Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. HC Wainwright lifted their target price on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Guggenheim reaffirmed a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday. Finally, Truist Financial lifted their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Buy” and an average target price of $80.00.

Insider Transactions at ANI Pharmaceuticals

In other news, CEO Nikhil Lalwani sold 28,965 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the completion of the transaction, the chief executive officer now directly owns 444,981 shares of the company’s stock, valued at $29,155,155.12. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Nikhil Lalwani sold 28,965 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the completion of the sale, the chief executive officer now owns 444,981 shares in the company, valued at $29,155,155.12. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Muthusamy Shanmugam sold 16,809 shares of the business’s stock in a transaction that occurred on Friday, April 19th. The stock was sold at an average price of $65.17, for a total value of $1,095,442.53. Following the sale, the chief operating officer now owns 782,620 shares of the company’s stock, valued at approximately $51,003,345.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 156,803 shares of company stock valued at $10,363,466. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $65.43 on Thursday. The company has a market cap of $1.38 billion, a P/E ratio of 77.89 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81. The stock has a 50-day moving average of $65.34 and a two-hundred day moving average of $58.75. ANI Pharmaceuticals, Inc. has a 1-year low of $36.99 and a 1-year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The business had revenue of $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. As a group, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.